SCHEMBL9067475

SCHEMBL9067475

C=CC(=O)NCCOP(=O)([O-])OCC[N+](C)(C)C

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.48
LMNA P02545 3/20 0.48
ESR1 P03372 1/20 0.48
ADORA3 P0DMS8 1/20 0.48
CDC25A P30304 1/20 0.48
AGTR1 P30556 1/20 0.48
AKT1 P31749 1/20 0.48
ADRA1A P35348 1/20 0.48
KCNH2 Q12809 1/20 0.48
PLA2G10 O15496 1/20 0.42
MAPK1 P28482 4/20 0.41
MEN1 O00255 2/20 0.41
GMNN O75496 2/20 0.41
MAPT P10636 2/20 0.41
BLM P54132 2/20 0.41
KMT2A Q03164 2/20 0.41
NPSR1 Q6W5P4 2/20 0.41
TP53 P04637 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9068058 0.90 LMNA (0.55) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL17370182 0.87 ZDHHC20 (0.39) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL9067631 0.82 SMN1; SMN2 (0.43) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL21987930 0.82 ZDHHC20 (0.36) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL15393542 0.81 SMN1; SMN2 (0.47) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL139079 0.78 SMN1; SMN2 (0.49) SMN1; SMN2LMNAESR1ADORA3CDC25A
Phosphoric Acid SCHEMBL17105884 0.77 ZDHHC20 (0.49) LMNAESR1ADORA3CDC25AAGTR1
Phosphoric Acid SCHEMBL28400128 0.77 ZDHHC20 (0.49) LMNAESR1ADORA3CDC25AAGTR1
SCHEMBL10823001 0.76 LMNA (0.57) SMN1; SMN2LMNAESR1ADORA3CDC25A
SCHEMBL25503763 0.76 ALDH1A1 (0.46) MAPK1CYP3A4TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 153 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4121802-B1 HIGH REFRACTIVE INDEX SILOXANE INSERT MATERIALS FOR EMBEDDED CONTACT LENSES ALCON INC (CH) 2024-07-17 EP claimed
EP-4076916-B1 WETTABLE SILICONE HYDROGEL CONTACT LENSES ALCON INC (CH) 2024-06-12 EP claimed
EP-4121801-B1 INSERT MATERIALS WITH HIGH OXYGEN PERMEABILITY AND HIGH REFRACTIVE INDEX ALCON INC (CH) 2024-04-17 EP claimed
EP-4118134-B1 PHOTOCHROMIC POLYDIORGANOSILOXANE VINYLIC CROSSLINKERS ALCON INC (CH) 2024-02-28 EP claimed
WO-2023228055-A1 UV/HEVL-FILTERING CONTACT LENSES ALCON INC. (CH) 2023-11-30 WO claimed
US-20230374306-A1 UV/HEVL-FILTERING CONTACT LENSES ALCON INC. (CH) 2023-11-23 US claimed
US-20230357478-A1 METHOD FOR MAKING EMBEDDED HYDROGEL CONTACT LENSES ALCON INC. (CH) 2023-11-09 US claimed
WO-2023209630-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2023-11-02 WO claimed
US-20230350100-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2023-11-02 US claimed
WO-2023121292-A1 POLYMER COMPOUND AND APPLICATION THEREOF 주식회사 삼양사 2023-06-29 WO claimed
US-10968319-B2 Silicone hydrogel contact lenses ALCON INC. (CH) 2021-04-06 US claimed
US-10962803-B2 Contact lenses with a lubricious coating thereon ALCON INC. (CH) 2021-03-30 US claimed
US-20200405747-A1 OPHTHALMIC COMPOSITIONS ALCON RESEARCH, LLC 2020-12-31 US claimed
WO-2020261185-A1 OPHTHALMIC COMPOSITIONS ALCON INC. (CH) 2020-12-30 WO claimed
US-20190300654-A1 METHOD FOR MAKING SILICONE HYDROGEL CONTACT LENSES ALCON RESEARCH, LTD. 2019-10-03 US claimed
US-20190263971-A1 SILICONE HYDROGEL CONTACT LENSES ALCON INC. (CH) 2019-08-29 US claimed
US-20190235277-A1 CONTACT LENSES WITH A LUBRICIOUS COATING THEREON ALCON INC. (CH) 2019-08-01 US claimed
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME KCI CO., LTD. (KR) 2014-09-25 US claimed
US-5461433-A Cleaning contact lens by immersing in solution containing copolymer where one of the monomers contains phsophate and tertiary ammonium groups NOF CORPORATION (JP) 1995-10-24 US claimed
EP-0537972-A1 Treating solution for contact lenses NOF CORPORATION (JP) 1993-04-21 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140288259-A1 SURFACE-MODIFIED ULTRAVIOLET BLOCKING POWDER AND ULTRAVIOLET BLOCKING COMPOSITION INCLUDING SAME C1QBP, PCTP, CD59 SMN1; SMN2 4469/4885LMNA 1745/4885ESR1 1530/4885
US-20200405747-A1 OPHTHALMIC COMPOSITIONS B4GALT1, B3GAT3, ALG1 SMN1; SMN2 4174/4885LMNA 1627/4885ESR1 4009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.